Iron absorption and iron status markers with increasing oral doses of FeSO4 in young women (study 1)
| . | . | Iron bioavailability . | Iron status . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Fe dose (mg) . | Day . | Fractional Fe absorption (%)* . | Fe absorbed (mg)* . | PHep (nM)* . | Plasma Fe (µg/mL)† . | Transferrin saturation (%)† . | PF (µg/L)* . | sTfR (mg/L)† . | Body iron stores (mg/kg BW)† . |
| 40 | 1 | NA | NA | 0.30 (0.12-0.48) | 0.63 (0.34) | 20.9 (15.1) | 10.0 (3.4-21.8) | 8.2 (4.2) | −0.05 (3.7) |
| 2 | 22.7 (14.7-57.1) | 9.1 (5.8-22.8) | 0.35 (0.11-0.77) | 0.55 (0.35) | 16.5 (11.7) | 9.1 (4.9-25.4) | 8.4 (3.8) | −0.8 (3.7) | |
| 9 | 19.4 (15.8-22.9) | 7.8 (6.3-9.2) | 0.59 (0.19-4.6) | 0.67 (0.61) | 21.3 (24.6) | 10.3 (5.1-40.8) | 7.1 (3.2) | 0.11 (4.1) | |
| 10 | 16.7 (11.8-20.7)‡ | 6.7 (4.7-8.3)‡ | 0.45 (0.05-4.3) | 0.60 (0.4) | 18.6 (16.3) | 15 (8.4-51.6) | 7.8 (3.5) | 1.2 (3.6) | |
| 23 | NA | NA | ND | ND | ND | 7.7 (4.2-20.1) | 5.6 (1.9) | −0.64 (2.4) | |
| 80 | 1 | NA | NA | 0.93 (0.1-3.7) | 1.2 (1.1) | 29.8 (12.8) | 19.4 (6.0-38.4) | 4.8 (1.7) | 3.5 (3.5) |
| 2 | 19.0 (10.5-30.9) | 15.2 (8.4-24.7) | 0.90 (0.40-2.2) | 0.80 (0.40) | 21.3 (8.4) | 17.7 (6.0-43.6) | 4.8 (1.6) | 3.5 (3.4) | |
| 9 | 18.2 (8.5-26.0) | 14.6 (8.5-26.0) | 1.1 (0.62-2.1) | 0.75 (0.41) | 20.9 (9.6) | 17.7 (6.5-51.1) | 4.5 (2.5) | 3.6 (3.4) | |
| 10 | 11.7 (8.4-24.7)§ | 9.3 (4.8-12.4)§ | 2.1 (0.98-5.1)¶ | 0.96 (0.60) | 23.5 (12.5) | 33 (24.1-55.0) | 3.9 (1.7) | 5.3 (2.7) | |
| 23 | NA | NA | ND | ND | ND | 15.2 (7.2-68.3) | 2.9 (1.5) | 4.8 (3.7) | |
| 160 | 1 | NA | NA | 0.93 (0.1-4.21) | 5.4 (9.3) | 29.5 (9.5) | 21.4 (8.8-39.9) | 4.6 (1.4) | 4.1 (3.1) |
| 2 | 15.9 (11.1-26.8) | 25.4 (17.8-42.9) | 0.95 (0.15-3.8) | 0.79 (1.4) | 23.2 (12.3) | 20.4 (5.8-63.1) | 4.8 (1.4) | 3.8 (3.0) | |
| 9 | 14.2 (6.1-48.3) | 22.7 (9.7-77.4) | 0.50 (0.20-1.3) | 0.84 (0.80) | 24.3 (5.8) | 16.6 (7.2-34.9) | 4.8 (1.0) | 3.1 (1.9) | |
| 10 | 9.7 (7.1-22.4)‖ | 15.6 (11.3-35.9)‖ | 1.56 (0.90-5.8)# | 0.89 (0.81) | 25.9 (10.2) | 42.1 (6.8-172)# | 4.6 (1.0) | 5.8 (3.3)** | |
| 23 | NA | NA | ND | ND | ND | 17.5 (10.5-22.0) | 3.5 (1.0) | 4.4 (1.3) | |
| 240 | 1 | NA | NA | 1.0 (0.1-2.4) | 0.85 (0.41) | 22.1 (12.6) | 16.1 (10.5-23.3) | 5.8 (1.7) | 2.3(2.1) |
| 2 | 13.0 (7.1-39.3) | 31.1 (17.0-94.3) | 0.95 (0.40-4.1) | 0.57 (0.22) | 15.2 (5.0) | 16.1 (12.2-28.3) | 6.0 (1.9) | 2.3 (2.1) | |
| 9 | 14.8 (7.4-42.6) | 35.5 (17.9-102.3) | 0.88 (0.23-5.6) | 0.54 (0.13) | 13.5 (3.0) | 21.9 (16.5-30.5) | 5.8 (1.7) | 3.3 (1.9) | |
| 10 | 7.5 (3.6-21.4)‡ | 18.1 (8.6-51.5)‡ | 3.4 (0.83-13.7)‡ | 0.56 (0.3) | 16.4 (12.4) | 33.4 (19.3-73.0) | 5.2 (1.6) | 2.3 (1.7) | |
| 23 | NA | NA | ND | ND | ND | 14.7 (10-33.3) | 3.7 (1.5) | 3.8 (2.5) | |
| . | . | Iron bioavailability . | Iron status . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Fe dose (mg) . | Day . | Fractional Fe absorption (%)* . | Fe absorbed (mg)* . | PHep (nM)* . | Plasma Fe (µg/mL)† . | Transferrin saturation (%)† . | PF (µg/L)* . | sTfR (mg/L)† . | Body iron stores (mg/kg BW)† . |
| 40 | 1 | NA | NA | 0.30 (0.12-0.48) | 0.63 (0.34) | 20.9 (15.1) | 10.0 (3.4-21.8) | 8.2 (4.2) | −0.05 (3.7) |
| 2 | 22.7 (14.7-57.1) | 9.1 (5.8-22.8) | 0.35 (0.11-0.77) | 0.55 (0.35) | 16.5 (11.7) | 9.1 (4.9-25.4) | 8.4 (3.8) | −0.8 (3.7) | |
| 9 | 19.4 (15.8-22.9) | 7.8 (6.3-9.2) | 0.59 (0.19-4.6) | 0.67 (0.61) | 21.3 (24.6) | 10.3 (5.1-40.8) | 7.1 (3.2) | 0.11 (4.1) | |
| 10 | 16.7 (11.8-20.7)‡ | 6.7 (4.7-8.3)‡ | 0.45 (0.05-4.3) | 0.60 (0.4) | 18.6 (16.3) | 15 (8.4-51.6) | 7.8 (3.5) | 1.2 (3.6) | |
| 23 | NA | NA | ND | ND | ND | 7.7 (4.2-20.1) | 5.6 (1.9) | −0.64 (2.4) | |
| 80 | 1 | NA | NA | 0.93 (0.1-3.7) | 1.2 (1.1) | 29.8 (12.8) | 19.4 (6.0-38.4) | 4.8 (1.7) | 3.5 (3.5) |
| 2 | 19.0 (10.5-30.9) | 15.2 (8.4-24.7) | 0.90 (0.40-2.2) | 0.80 (0.40) | 21.3 (8.4) | 17.7 (6.0-43.6) | 4.8 (1.6) | 3.5 (3.4) | |
| 9 | 18.2 (8.5-26.0) | 14.6 (8.5-26.0) | 1.1 (0.62-2.1) | 0.75 (0.41) | 20.9 (9.6) | 17.7 (6.5-51.1) | 4.5 (2.5) | 3.6 (3.4) | |
| 10 | 11.7 (8.4-24.7)§ | 9.3 (4.8-12.4)§ | 2.1 (0.98-5.1)¶ | 0.96 (0.60) | 23.5 (12.5) | 33 (24.1-55.0) | 3.9 (1.7) | 5.3 (2.7) | |
| 23 | NA | NA | ND | ND | ND | 15.2 (7.2-68.3) | 2.9 (1.5) | 4.8 (3.7) | |
| 160 | 1 | NA | NA | 0.93 (0.1-4.21) | 5.4 (9.3) | 29.5 (9.5) | 21.4 (8.8-39.9) | 4.6 (1.4) | 4.1 (3.1) |
| 2 | 15.9 (11.1-26.8) | 25.4 (17.8-42.9) | 0.95 (0.15-3.8) | 0.79 (1.4) | 23.2 (12.3) | 20.4 (5.8-63.1) | 4.8 (1.4) | 3.8 (3.0) | |
| 9 | 14.2 (6.1-48.3) | 22.7 (9.7-77.4) | 0.50 (0.20-1.3) | 0.84 (0.80) | 24.3 (5.8) | 16.6 (7.2-34.9) | 4.8 (1.0) | 3.1 (1.9) | |
| 10 | 9.7 (7.1-22.4)‖ | 15.6 (11.3-35.9)‖ | 1.56 (0.90-5.8)# | 0.89 (0.81) | 25.9 (10.2) | 42.1 (6.8-172)# | 4.6 (1.0) | 5.8 (3.3)** | |
| 23 | NA | NA | ND | ND | ND | 17.5 (10.5-22.0) | 3.5 (1.0) | 4.4 (1.3) | |
| 240 | 1 | NA | NA | 1.0 (0.1-2.4) | 0.85 (0.41) | 22.1 (12.6) | 16.1 (10.5-23.3) | 5.8 (1.7) | 2.3(2.1) |
| 2 | 13.0 (7.1-39.3) | 31.1 (17.0-94.3) | 0.95 (0.40-4.1) | 0.57 (0.22) | 15.2 (5.0) | 16.1 (12.2-28.3) | 6.0 (1.9) | 2.3 (2.1) | |
| 9 | 14.8 (7.4-42.6) | 35.5 (17.9-102.3) | 0.88 (0.23-5.6) | 0.54 (0.13) | 13.5 (3.0) | 21.9 (16.5-30.5) | 5.8 (1.7) | 3.3 (1.9) | |
| 10 | 7.5 (3.6-21.4)‡ | 18.1 (8.6-51.5)‡ | 3.4 (0.83-13.7)‡ | 0.56 (0.3) | 16.4 (12.4) | 33.4 (19.3-73.0) | 5.2 (1.6) | 2.3 (1.7) | |
| 23 | NA | NA | ND | ND | ND | 14.7 (10-33.3) | 3.7 (1.5) | 3.8 (2.5) | |
BW, body weight; NA, not applicable; ND, not determined; PF, plasma ferritin; PHep, plasma hepcidin; STfR, soluble transferrin receptor.
Doses are given on days 2, 9, and 10 at 08:00 am immediately after iron status assessment; for 40, 80 and 240 mg: n = 6; for 160 mg: n = 7.
Geometric means (range).
Means (SD).
Different from day 7 and day 2 (P < .05).
Different from day 7 and day 2 (P < .01).
Different from day 2 (P = .08).
Different from day 7 and day 2 (P < .001).
Different to all other time points (P < .05).
Different from day 2 (P < .05).